The Japan Society of Hepatology
In June 2018, I was fortunate to be appointed the 9th Director General of the Japan Society of Hepatology, succeeding Professor Kazuhiko Koike in the post. As I take on this role, I very much appreciate your support and cooperation.
Since its establishment in 1965, the Japan Society of Hepatology has been committed to advancing nationwide medical care of and research into hepatitis and liver cancer and to training young doctors and researchers. As a society, we have actively arranged educational activities such as seminars open to members of the public and advised on the development of national measures and policies. With the great advances made in medical care and research on hepatitis C in the last quarter century, safe and highly effective antiviral therapies have become widely available. Now, we are facing the emerging problem of liver diseases that develop following the eradication of viruses. Japan provides internationally outstanding medical care for liver cancer patients. However, given that many molecular targeted agents and other treatments are expected to become widely available into the future, we must now aim for even greater improvements. New agents for liver cirrhosis (end-stage liver disease) have become available in the last 10 years, and comprehensive measures are now needed to actually improve prognosis. Also, our society must address a wide range of issues, including non-alcoholic steatohepatitis as the most frequently occurring liver disease, failure of complete virus eradication in hepatitis B, and alcoholic liver disease and drug-induced liver injury.
The Japan Society of Hepatology is fully aware of the current situation and remains committed to further advancing research in hepatology and medical care for liver diseases and to guiding improvements over the next quarter century. In these efforts, the support and cooperation of society members and the public continue to be greatly appreciated.